Emergent BioSolutions | EBS - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amarin USD 449.41M 9.87M 2026-03
ANI Pharmaceuticals USD 562.3M 21.58M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Emergent BioSolutions USD 649.3M 47.9M 2023-12
Exelixis USD 1.94B 225.57M 2026-03
Glaxosmithkline GBP 22.06B 360M 2025-12
Heron Therapeutics USD 9.14M 4.15M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Ironwood Pharmaceuticals USD -217.14M 44.69M 2026-03
Lexicon Pharmaceuticals USD 202.86M 95.32M 2026-03
Lonza CHF 9.13B 513M 2025-12
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Myriad Genetics USD 337.4M 30.6M 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Pacira USD 653.89M 39.22M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
United Therapeutics USD 5.9B 1.2B 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Xoma USD 87.94M 15.5M 2025-09